Results · Apr-Jun 2026 · filed 7 Aug 2026
Gujarat Themis Biosyn Q1 FY27 results
StrongStrong: sales up 10% or more & profit up 20% or more on the same quarter last year, with a wider operating margin.
Sales grew 22% to ₹43.8 crore from ₹35.9 crore in Apr-Jun 2025.
Operating profit grew 49% to ₹20.8 crore, an operating margin of 47.5% (up 8.7 points from a year ago).
Net profit grew 22% to ₹11.1 crore from ₹9.1 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −1%, net profit +2%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 43.8 | 35.9 | +22% |
| Operating profit (EBITDA) | 20.8 | 13.9 | +49% |
| Operating margin | 47.5% | 38.8% | +8.7 pts |
| Net profit | 11.1 | 9.1 | +22% |
Standalone figures. Margins & ratios change in percentage points (pts).
The earnings call
Apr–Jun 2026 revenue grew 22.1% to ₹43.8 crore with EBITDA margin expanding 867 bps to 47.5%. Management is transforming GTBL into a fermentation-led CDMO through expanded capacity, MicroBiopharm Japan acquisition & Sanofi brand portfolio to capture higher-value opportunities across the pharmaceutical value chain.
The last 7 quarters
Filings that week
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 9 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 7 Aug 2026Results- Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30Th June 2026
- 7 Aug 2026Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.08.2026
- 5 Aug 2026Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
- 4 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.